Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
TOT BIOPHARM International Co. Ltd. ( (HK:1875) ) just unveiled an announcement.
TOT BIOPHARM International Co. Ltd. has announced a proposal to change its English name to BioDlink International Company Limited, subject to shareholder and regulatory approval. This name change is intended to better align with the company’s business strategy and enhance its corporate image, without affecting current shareholders’ rights or the company’s operations.
The most recent analyst rating on (HK:1875) stock is a Buy with a HK$3.00 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.
More about TOT BIOPHARM International Co. Ltd.
TOT BIOPHARM International Co. Ltd. operates in the biopharmaceutical industry, focusing on the development and commercialization of oncology drugs. The company is committed to providing innovative therapeutic solutions to meet the needs of cancer patients.
Average Trading Volume: 165,256
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.39B
See more insights into 1875 stock on TipRanks’ Stock Analysis page.